Animal experiments have also reported significant increases in serum HMGB1 levels in mouse models of chronic hypoxia, and demonstrated that exogenous recombinant HMGB1 can exacerbate pulmonary arterial hypertension, whereas the administration of HMGB1-neutralizing antibodies can slow its progression 10. Here, HMGB1 is linked to pulmonary arterial hypertension.